Navigation Links
Proteomics Study Reveals That Genes Involved in Invertebrate Longevity Have Surprising Parallels in Humans.
Date:3/13/2009

SALT LAKE CITY, March 13 /PRNewswire/ -- Prolexys Pharmaceuticals announced today the publication of the discovery of genes that are likely to have a role in the aging process of humans. The findings result from research on the human equivalents of proteins from simple animals which confer long life in those species. The evidence suggests that these proteins are more likely to interact with other proteins in a large atlas of mapped interactions. Furthermore, the investigators were able to show that the protein associations also correlate with differences in gene expression between young and old humans. Though the existence of longevity-extending genes has been known for experimental organisms such as yeast, roundworms and flies, this is the first demonstration that similar genes have a role in the aging process of humans.

The proteins involved are defined as a network of 175 human equivalents of known invertebrate longevity genes and 2163 additional proteins in a complex network involving 3271 interactions. The research, published in the March 13, 2009 issue of PLoS Genetics, was a collaboration of scientists at Prolexys, The Buck Institute for Age Research in Novato, California, University of California in Berkeley and McMaster University in Hamilton, Ontario.

"This work continues to demonstrate that high-throughput screening for protein interactions combined with genetic and functional validation provides an opportunity to investigate complex biological processes such as aging. Furthermore, we would like to encourage scientists interested in aging and longevity to mine these data made available in the study," said Dr. Sudhir Sahasrabudhe, Chief Scientific Officer of Prolexys Pharmaceuticals.

"This establishes a similarity in aging process among diverse species that is perhaps a lot broader than many of us may have expected," says Robert Hughes, lead author of the study.

About Prolexys Pharmaceuticals, Inc.:

Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's current therapeutic focus is on cancer. Prolexys scientists have developed proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include:

a) A solid tumor oncology program in Phase 1 clinical trials with a small molecule, PRLX 93936, which targets advanced solid tumors that are otherwise refractory to the standard of care therapies.

b) A colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade.

Visit www.prolexys.com for more information.

About the Buck Institute:

The Buck Institute is the only freestanding institute in the United States that is devoted solely to basic research on aging and age-associated disease. The Institute is an independent nonprofit organization dedicated to extending the healthspan, the healthy years of each individual's life. The National Institute on Aging designated the Buck a "Nathan Shock Center of Excellence in the Biology of Aging," one of just five centers in the country. Buck Institute scientists work in an innovative, interdisciplinary setting to understand the mechanisms of aging and to discover new ways of detecting, preventing and treating conditions such as Alzheimer's and Parkinson's disease, cancer, diabetes and stroke. Collaborative research at the Institute is supported by new developments in genomics, proteomics and bioinformatics technology. For more information: www.buckinstitute.org.


'/>"/>
SOURCE Prolexys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Covance Purchases Equity Stake in Caprion Proteomics
2. Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics
3. Sigma-Aldrich Announces New Prestige Antibodies(TM) Line for Proteomics and Cell Biology Researchers
4. Bruker Announces Availability of New HUPO World Congress Proteomics Posters on Web Site
5. Angiotech announces positive results from Bio-Seal(TM) clinical study
6. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
7. Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma
8. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
9. QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy
10. New Study Reports Improved Patient Outcomes for Breast Cancer Patients
11. Mouse study reveals genetic component of empathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... Parsippany, NJ (PRWEB) , ... June 20, 2017 , ... ... OHAUS makes the transition from being a trusted supplier in the weighing industry, to ... including cell extractions, ELISA essays, enzyme reactions, immunoassays, hybridizations and more, allowing for ...
(Date:6/19/2017)... , ... June 19, 2017 , ... ... all service activities supporting EDETEK’s products including training, implementation, support, and client process ... his new role. He has previously held leadership roles for service providers and ...
(Date:6/19/2017)... ... June 19, 2017 , ... Tunnell Consulting has been solving ... of the biggest challenges faced by life sciences, biotech and pharmaceuticals companies today is ... Kati Abraham , who is well known in the industry and brings significant ...
(Date:6/16/2017)... Lexington, Massachusetts (PRWEB) , ... June 16, 2017 ... ... in medical device compliance and commercialization, has just announced two more sessions of ... of the series will focus on the world of online templates for design ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
(Date:3/23/2017)... India , March 23, 2017 The report "Gesture ... Touchless Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, ... at a CAGR of 29.63% between 2017 and 2022. ... ... ...
Breaking Biology News(10 mins):